Skip to main content
RESMED INC logo

RESMED INC — Investor Relations & Filings

Ticker · RMD LEI · 254900O2VD7IQ5OGI615 ASX Manufacturing
Open in API
Filings indexed 1,641 across all filing types
Latest filing 2013-07-18 Legal Proceedings Report
Country AU Australia
Listing ASX RMD

About RESMED INC

https://www.resmed.com

ResMed Inc. is a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for the management of sleep-disordered breathing, chronic obstructive pulmonary disease, and other respiratory conditions. The company’s primary product portfolio includes continuous positive airway pressure (CPAP) devices, bilevel machines, and a variety of masks and accessories designed to improve patient adherence and comfort. ResMed distinguishes itself through its focus on digital health, offering integrated software platforms that enable remote patient monitoring and data-driven clinical insights for healthcare providers. Additionally, the company provides software-as-a-service (SaaS) solutions to support out-of-hospital care settings, including home health, hospice, and skilled nursing facilities, aiming to improve patient outcomes and reduce overall healthcare costs.

Recent filings

Filing Released Lang Actions
ResMed Succeeds in Patent Fight Against APEX 1 page
Legal Proceedings Report Classification · 95% confidence The document is a press release announcing the outcome of a patent infringement legal case involving ResMed and APEX Medical Corp. It details the administrative law judge's decision at the International Trade Commission to stop the importation and sale of infringing products. There is no financial data, no mention of financial results, no report publication, no shareholder meeting information, or any other regulatory filing type. The content is primarily about legal proceedings and enforcement of intellectual property rights. Therefore, the document best fits the category of Legal Proceedings Report (LTR). The document length is short and it is not a report publication announcement or certification, so those categories are excluded.
2013-07-18 English
Q4 & Fiscal Year-End, 2013 Results Conference Call 1
Call Transcript Classification · 90% confidence The document is a short announcement about an upcoming conference call and webcast to discuss the fourth quarter and fiscal year-end 2013 results. It includes details on how to participate in the call and when the replay will be available. There is no actual financial data or detailed report content included. The document is under 5,000 characters and serves as a notification for an event related to earnings results, not the earnings release itself or a transcript. Therefore, it fits best as a Call Transcript (CT) announcement or an Earnings Release (ER) announcement. However, since it is announcing the conference call specifically, it is best classified as a Call Transcript (CT) type, as it is about the call event rather than the earnings release document itself.
2013-06-27 English
RMD ANNOUNCES EXCHANGE RATE FOR DIVIDEND 1 page 85.
Notice of Dividend Amount Classification · 100% confidence The document is a short announcement from ResMed Inc. regarding the exchange rate for an upcoming dividend payment. It specifies the dividend amount in Australian dollars and US dollars, the record date, and the payment date. There is no detailed financial data, analysis, or comprehensive report content. The document is clearly an announcement about dividend payment details rather than a full dividend report or annual/quarterly report. The length is only 2460 characters, which is short and typical for a dividend announcement. Therefore, the appropriate classification is Notice of Dividend Amount (DIV).
2013-05-22 English
ResMed and University of Sydney Partnership Agreement 2 pages 219.3KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing a partnership and funding agreement between ResMed Limited and The University of Sydney to support research in sleep-disordered breathing and biomedical engineering. It discusses the financial commitment ($AU25 million) and the establishment of academic chairs, but it does not contain any financial statements, regulatory filings, or detailed financial performance data. The document is informational and promotional in nature, focusing on the partnership and research funding rather than reporting financial results or regulatory compliance. It is not an annual report, earnings release, regulatory filing, or any other formal financial or governance document. Therefore, the most appropriate classification is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2013-05-13 English
Form 10Q for Qtr ended March 31, 2013 39 pages 301.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FORM 10-Q' and is described as a 'Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934' for the quarterly period ended March 31, 2013. It contains detailed financial statements including balance sheets, statements of income, cash flows, notes to financial statements, management's discussion and analysis, risk factors, and other comprehensive financial information. The length of the document is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or certification. The presence of unaudited condensed consolidated financial statements and management's discussion confirms it is a quarterly financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2013
2013-05-01 English
Record Financial Results for Q/E & 9 Months Mar 31, 2013 4 pages 107.3KB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of quarterly financial results for ResMed Inc. for the quarter and nine months ended March 31, 2013. It includes comprehensive financial data such as revenue, net income, earnings per share, expenses, and balance sheet items. The text also contains management commentary on performance and product launches, as well as dividend declaration details. The presence of detailed financial statements and analysis for a period shorter than a full fiscal year (quarter and nine months) indicates this is an Interim / Quarterly Report. It is not merely an earnings release since it contains substantive financial data and analysis, nor is it an Annual Report or other filing type. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2013
2013-04-25 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.